HPRA Drug Safety Newsletter Edition 75
Download:
hpra-drug-safety-newsletter-edition-75.pdf
256 KB
The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:
- Withdrawal of fusafungine-containing medicinal products
- Updated advice on the risk of diabetic ketoacidosis during treatment with SGLT2 inhibitors
- Risk of pneumonia with inhaled corticosteroids for chronic obstructive pulmonary disease (COPD)
- Risk of hepatitis B reactivations with BCR-ABL Tyrosine Kinase Inhibitors (TKIs)
- Aflibercept (Zaltrap)-Minimising the risk of ONJ
- Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter
« Back